Jove
Visualize
Contact Us

Related Experiment Videos

Enzymatic vitreous disruption.

A Gandorfer1

  • 1Vitreoretinal and Pathology Unit, Augenklinik der Ludwig-Maximilians-Universität, München, Germany. arnd.gandorfer@med.uni-muenchen.de

Eye (London, England)
|February 23, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Sunrise Ultraviolet Spectropolarimeter and Imager: Standalone Polarimetric Calibration.

Solar physics·2025
Same author

[Retinal detachment in children and adolescents. Specific clinical features].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2019
Same author

[Clinicopathological correlations at the vitreoretinal interface].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2015
Same author

[Pharmacological vitreolysis].

Klinische Monatsblatter fur Augenheilkunde·2010
Same author

[Vitreoretinal degenerative macular diseases].

Klinische Monatsblatter fur Augenheilkunde·2010
Same author

[Ballsports related eye injuries].

MMW Fortschritte der Medizin·2009
Same journal

Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease.

Eye (London, England)·2026
Same journal

Oculomics and the NHS: A UK opportunity to translate eye-derived biomarkers into population health.

Eye (London, England)·2026
Same journal

Long-term follow-up and outcomes of a Diabetic Eye Screening Programme in patients aged 80 with no diabetic eye disease at baseline: should we be routinely screening this cohort?

Eye (London, England)·2026
Same journal

Real world experience with faricimab in switched neovascular AMD and evaluation of reloading versus interval matching regimes.

Eye (London, England)·2026
Same journal

"When the lens drew a continent: a cartographic clue to Alport syndrome".

Eye (London, England)·2026
Same journal

Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity.

Eye (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Enzymatic vitreous disruption uses enzymes to detach the vitreous from the retina. Chondroitinase, hyaluronidase, dispase, and microplasmin are explored for treating vitreoretinal conditions.

Area of Science:

  • Ophthalmology
  • Biochemistry
  • Regenerative Medicine

Background:

  • Enzymatic vitreous disruption involves cleaving the vitreoretinal junction to induce posterior vitreous detachment (PVD) and vitreous liquefaction.
  • Various enzymes like chondroitinase, hyaluronidase, dispase, and plasmin have been investigated for this purpose.

Purpose of the Study:

  • To review current knowledge on enzymatic vitreous disruption.
  • To discuss enzyme candidates for basic and clinical research in ophthalmology.

Main Methods:

  • Review of existing literature on enzymatic vitreous disruption.
  • Analysis of experimental and clinical data for different enzyme candidates.

Main Results:

  • Chondroitinase demonstrated PVD induction and epiretinal membrane removal in experimental settings.

Related Experiment Videos

  • Hyaluronidase showed vitreous liquefaction in a phase III trial for diabetic vitreous hemorrhage.
  • Dispase induces PVD but causes retinal damage, used in animal models; plasmin is unstable, but microplasmin shows promise for vitreomacular traction.

    • Conclusions:

    • Enzymatic vitreous disruption holds potential for treating various vitreoretinal diseases.
    • Microplasmin is a promising candidate for clinical applications, particularly in vitreomacular traction.